Clinical Trial Detail

NCT ID NCT02869789
Title A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.